

February 8, 2024

The Manager – Listing  
**BSE Limited**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that based on the recommendation of the Nomination & Remuneration Committee meeting, the Board of Directors have appointed Ms. Bhavana Agrawal as an Additional Director and a Whole-time Director on the Board of the Company, with effect from February 8, 2024. She will take up this responsibility in addition to the duties of being the Chief Financial Officer at AstraZeneca Pharma India Limited.

Further, we wish to inform that Ms. Weiyang Sarah Wang, Non-Executive Director has resigned from the office of Director of AstraZeneca Pharma India Limited with effect from close of working hours on February 8, 2024 due to changes in her role and responsibilities that she will continue to pursue within AstraZeneca. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for her contribution during her tenure in the Company.

As required under the Schedule III of the listing regulations, the resignation letter received from Ms. Sarah Wang is attached herewith as Annexure - A

Further, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as Annexure – B.

Please take the same on record.

Thanking you,

**For AstraZeneca Pharma India Limited**

**Manasa. R**  
**Company Secretary**

Date: Feb 8, 2024

To:  
The Board of Directors  
AstraZeneca Pharma India Limited  
Bangalore  
India


Dear All,

Subject: Resignation from Board and Committees

I hereby submit my resignation as the Director of AstraZeneca Pharma India Limited ('the Company) and from the Audit Committee, Stakeholders' Relationship Committee and Corporate Social Responsibility Committee of the Company, all with effect from the close of business hours (IST) on February 8, 2024. The reason is due to changes in my role and responsibilities at AstraZeneca.

I would like to express and record my sincere gratitude to my fellow Board members and the Company management for their support and guidance to me during my time on the Board. I will remember fondly my experience working with all of you and I wish you and the Company great success in the future.

Sincerely,

  
Weiyang Sarah Wang

### Annexure - B

Sl.	Particulars	Information about the change	
		Resignation of Ms. Weiyng Sarah Wang	Appointment of Ms. Bhavana Agrawal
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation of Ms. Weiyng Sarah Wang as a Director of the Company.	Appointment of Ms. Bhavana Agrawal as an Additional Director and a Whole-time Director of the Company.
2.	Date of appointment/cessation (as applicable) & term of appointment	February 8, 2024 (cessation)	February 8, 2024 (appointment)
3.	Brief profile (in case of appointment)	-	<p>Ms. Bhavana Agrawal is currently the Chief Financial Officer of AstraZeneca Pharma India Limited.</p> <p>She comes with over two decades of finance experience and has worked across multiple geographies &amp; businesses. She played various roles with GE prior to joining AZ and her last responsibility was based out of Dubai as a CFO - Services business at GE Healthcare for Middle East, Africa &amp; Russia where she provided Finance leadership to \$300M revenue business across 30+ countries.</p> <p>With her expertise around Commercial Finance, P&amp;L Management, financial planning /Analysis, Cash flow management, Accounting &amp; Controls, she was a strategic finance partner for businesses with consistent performance in maximising revenue, margin &amp; cash. She carries strong leadership with proven record in creating positive team culture &amp; growth. Prior to CFO role, she had performed multiple roles across finance domain between 2003 to 2015 in Dubai and India for GE.</p> <p>Bhavana Agrawal is an All-India rank holder as a Chartered Accountant. Earlier she completed</p>

			her Bachelor of Business Studies in Delhi University.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	-	Neither related to any director on the Board of Directors of the Company nor with the promoter of the Company.
5.	Affirmation pursuant to circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	-	Ms. Bhavana Agrawal is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.